Promising combo tackles tough lymphoma
NCT ID NCT07279584
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of the drug golidocitinib plus chemotherapy (gemcitabine and oxaliplatin) in 31 adults with relapsed or refractory peripheral T-cell lymphoma, a rare and aggressive blood cancer. The goal is to see if the combo safely shrinks tumors and delays disease worsening. Participants must have had at least one prior treatment and have measurable tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- golidocitinib combined with gemcitabine and oxaliplatin
- What this could lead to
- If successful, this combination could offer a new treatment option for people with relapsed or refractory peripheral T-cell lymphoma, potentially improving tumor shrinkage and delaying disease progression.
- What could go wrong
- This is a small, early-phase trial with only 31 participants, so results may not apply to all patients. The combination may cause side effects like low blood counts or nerve damage, and it is not yet known if it works better than existing therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMAS (PTCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.